ScripKRAS inhibition maybe suitable for a tumor-agnostic drug development approach, but Amgen Inc. hasn't decided yet if that's the path it will take with AMG 510 based on the initial set of Phase I data
In VivoCompany Changes ALLEN , Jon To: Alphatec Holdings Inc. , EVP, Commercial Ops. (December) From: Wright Medical Group NV, VP, Healthcare Economics & Reimbursement Phone: 760-431-9286 ANDERSON ,
ScripIN VITRO DIAGNOSTICS Arch Biopartners Inc. University of Alberta Arch Biopartners gets option to University of Alberta 's IBS diagnostic technology Public Canadian biotech Arch Biopartners In